AI Article Synopsis
- Lung cancer is the leading cause of cancer-related deaths in Western countries, with a very low 5-year survival rate of 15%, primarily due to late-stage detection and ineffective treatments.
- There is a pressing need for new methods to diagnose and predict lung cancer progression to facilitate better treatment options.
- Proteomics offers a promising approach to identify new biomarkers and therapeutic targets for lung cancer, as traditional DNA-based methods have shown limited effectiveness in sensitivity and reliability.
Article Abstract
Lung cancer is the most common cause of cancer death in both men and women in Western countries, with a 5-year survival rate of 15%, which is among the lowest of all cancers. The high mortality from lung cancer is due not only to the late stage diagnosis but also to the lack of effective treatments even for patients diagnosed with stage I lung cancer. Therefore, there is an urgent need to identify new markers for early diagnosis and prognosis that could serve to open novel therapeutic avenues. Proteomics can represent an important tool for the identification of biomarkers and therapeutic targets for lung cancer since DNA-based biomarkers did not prove to have adequate sensitivity, specificity, and reproducibility. In this paper we will describe studies focused on the identification of new diagnostic, prognostic, and predictive markers for lung cancer, using proteomics technologies.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3196861 | PMC |
| http://dx.doi.org/10.1155/2011/726869 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!